Table of Contents

Aapro, M. S., Alberts, D. S.: High-dose Dexamethasone for Prevention of *cis*-Platin-induced Vomiting 11
Acton, E. M., see Peters, J. H., et al. 65
Aherne, G. W., Marks, V.: A Radioimmunoassay for VP16-213 in Plasma 117
Aisner, J., Echo, D. A. Van, Whitacre, M., Wiernik, P. H.: A Phase I Trial of Continuous Infusion VP16-213 (Etoposide) 157
Aisner, J., see Echo, D. A. Van, et al. 237
Aisner, J., Whitacre, M., Echo, D. A. Van, Wesley, M., Wiernik, P. H.: Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the Treatment of Small Cell Lung Cancer 187
Aisner, J., Whitacre, M., Echo, D. A. Van, Wiernik, P. H.: Doxorubicin Cyclophosphamide and VP16-213 (ACE) in the Treatment of Small Cell Lung Cancer 241
Alberts, D. S., see Aapro, M. S. 11
Alburquerque Carbuccia, H., see Perez Manga, G., et al. 227
Alburquerque Carbuccia, H., see Perez Manga, G., et al. 231
Allen, L. M., Tejada, F., Okonmah, A. D., Nordqvist, S.: Combination Chemotherapy of the Epipodophyllotoxin Derivatives, Teniposide, and Etoposide. A Pharmacodynamic Rationale? 151
Anderson, G., Peel, E. T.: Monoagent VP16-213 in Bronchogenic Carcinoma and Report of Toxicity in Combination with Other Cytotoxics 239
Arnold, A., see Lawrie, S., et al. 236
Arnold, A. M., Whitehouse, J. M. A.: Interaction of VP16-213 with the DNA Repair Antagonist Chloroquine 123
Arwidi, Å., see Eyben, F. E. von, et al. 195
Au, J. L.-S., Sadée, W.: Stereoselective Metabolism of Ftorafur (R,S-1-(Tetrahydro-2-furanyl)-5-Fluorouracil) 55
Aur, R. J., see Rivera, G., et al. 169
Avery, T. L., see Rivera, G., et al. 169
Ayres, D. C., Lim, C. K.: Modification of the Pendant Ring of Podophyllotoxin 99

Bagshawe, K. D., see Begent, R. H. J., et al. 243
Bagshawe, K. D., see Newlands, E. S. 211
Barrett, A., Peckham, M. J., McElwain, T. J.: Bleomycin Vp16-213 and Cis-Platinum (BEP): A Lower Toxicity Combination for Selected Patients with Germ Cell Tumours 243
Barrett, A., see Taylor, R. E., et al. 175
Bedogni, P., see Canetta, R., et al. 93
Beer, M., see D'Incalci, M., et al. 141
Begent, R. H. J., Newlands, E. S., Rustin, G. J. S., Bagshawe, K. D.: Combination Chemotherapy for Advanced Malignant Teratoma 243
Bianchi, C., see Morasca, L., et al. 209
Birch, R., see Oldham, R. K., et al. 242
Blumenschein, G. R., see Schell, F. C. et al. 244
Boesen, E. M., see Corringham, R. E. T. 240
Bollag, W.: Arotinoids. A New Class of Retinoids with Activities in Oncology and Dermatology 27
Bowman, W. P., see Rivera, G., et al. 169
Broggini, M., see Colombo, T., et al. 127
Bruyne, G. De, see Mareel, M., et al. 239
Bukowski, R. M., see Mortimer, J., et al. 215

Canetta, R., Hilgard, P., Florentine, S., Bedogni, P., Lenaz, L.: Current Development of Podophyllotoxins 93
Carbone, A., see Tirelli, U., et al. 173
Carter, S. K.: Predictors of Response and Their Clinical Evaluation 1
Carter, S. K., see Sikic, B. I., et al. 241
Casali, W., see Morasca, L., et al. 209
Casazza, A. M., see Marco, A. Di, et al. 15
Casper, E., see Chapman, R., et al. 205
Cauwenberge, R. Van, see Mareel, M., et al. 239
Cavalli, F.: VP16-213 (Etoposide). A Critical Review of Its Activity 81
Cavalli, F., see D'Incalci, M., et al. 141
Chak, L., see Sikic, B. I., et al. 241
Chapman, R., Itri, L., Gralla, R., Kelsen, D., Casper, E., Golbey, R.: Phase II Trial of VP16-213 in Non-small Cell Lung Cancer (NSCLC) 205
Chuang, V. P., see Patt, Y. Z., et al. 238
Cogo, R., see Morasca, L., et al. 209
Colombo, T., Broggini, M., Torti, L., Erba, E., D'Incalci, M.: Pharmacokinetics of VP16-213 in Lewis Lung Carcinoma Bearing Mice 127
Colvin, M., see Jardine, I., et al. 237
Conter, V., see D'Incalci, M., et al. 141
Corringham, R. E. T., Boesen, E. M.: Oral Epipodophyllotoxin and Chlorambucil: A Preliminary Study in Small Cell Carcinoma of Lung 240
Cortés Funes, H., Dominguez, P., Torrubia, A. P., Lanzos, E., Mendez, M., Miendiola, C.: Treatment of Small Cell Lung Cancer with a Combination of VP16-213 and Cyclophosphamide with Cisplatin or Radiotherapy 181
Creaven, P. J.: The Clinical Pharmacology of VM26 and VP16-213. A Brief Overreview 133
Crom, W. R., see Evans, W. E., et al. 147
Crooke, S. T., see Kalvin, D. M., et al. 41
Curry, M. E., see Issell, B. F., et al. 113

Dahl, G. V., see Look, A. T. et al. 161
Dahl, G. V., see Rivera, G., et al. 169
Dally, M. B., see Harper, P. G., et al. 179
Daniels, J. R., see Sikic, B. I., et al. 241
Danø, K., see Marco, A. Di, et al. 15
Dennis, L. Y., see Hill, B. T., et al. 21
Dhafir, R. A., see Issell, B. F., et al. 239
D'Incalci, M., see Colombo, T., et al. 127
D'Incalci, M., Farina, P., Sessa, C., Mangioni, C., Conter, V., Masera, G., Rocchetti, M., Pisoni, M. B., Piazza, E., Beer, M., Cavalli, F.: Pharmacokinetics of VP16-213 Given by Different Administration Methods 141
Dodson, M., see Lawrie, S., et al. 236
Dombernowsky, P., see Pedersen, A. G., et al. 242
Dominguez, P., see Cortés Funes, H., et al. 181
Dow, L., see Evans, W. E., et al. 147
Dragonetti, C., see Mareel, M., et al. 239

Echo, D. A. Van, Aisner, J., Whitacre, M., Wiernik, P. H.: A Phase I–II Trial of Continuous Infusion VP16-213 237

Echo, D. A. Van, see Aisner, J., et al. 157
Echo, D. A. Van, see Aisner, J., et al. 187
Echo, D. A. Van, see Aisner, J., et al. 241
Einhorn, L., see Oldham, R. K., et al. 242
Erba, E., see Colombo, T., et al. 127
Escudero, C., see Martinez, J., et al. 240
Esparza, L., see Schell, F. C., et al. 223
Esparza, L., see Schell, F. C., et al. 244
Evans, W. E., Sinkule, J. A., Crom, W. R., Dow, L., Look, A. T., Rivera, G.: Pharmacokinetics of Teniposide (VM26) and Etoposide (VP16-213) in Children with Cancer 147
Eyben, F. E. von, Arwidi, Å., Hellekant, C., Jonsson, K., Lindahl, S. Å., Mattsson, W., Tennvall, L.: Vincristine, Adriamycin, Cyclophosphamide, and Etoposide (VP16-213) in Small-cell Anaplastic Carcinoma of the Lung 195

Farina, P., see D'Incalci, M., et al. 141
Florentine, S., see Canetta, R., et al. 93
Franchin, G., see Tirelli, U., et al. 173

Galligioni, E., see Tirelli, U., et al. 173
Geddes, D. M., see Harper, P. G., et al. 179
Golbey, R., see Chapman, R., et al. 205
Gomez, R. G., see Madrigal, P. A., et al. 203
González Larriba, J. L., Montero Carcia, J. M., Ordoñez Gallego, A., Juarez Alonso, S.: VP16-213 Phase II Study Small Cell Lung Carcinoma 240
Goodyear, M. D. E., Mackay, I. R., Russell, I. S.: Delayed Recovery of Peripheral Blood Cell Numbers after Adjuvant Cytotoxic Chemotherapy for Stage II Breast Cancer 37
Gordon, G. R., see Peters, J. H., et al. 65
Gracia, J. M., Jimenez, A.: Chemotherapy Combination with Cyclophosphamide (CTX) Adriamycin (ADM), Vincristine (VCR), and VP16-213 in Small Cell Carcinoma of the Lung (SCCL) 199
Gralla, R., see Chapman, R., et al. 205
Greco, F. A., see Oldham, R. K., et al. 242
Grigoletto, E., see Tirelli, U., et al. 173
Gunderson, L. L., see Swartz, M. R., et al. 238

Harper, P. G., Dally, M. B., Geddes, D. M., Spiro, S. G., Smyth, J. F., Souhami, R. L.: Epipodophyllotoxin (VP16-213) in Small Cell Carcinoma of the Bronchus Resistant to Initial Combination Chemotherapy 179
Hellekant, C., see Eyben, F. E. von, et al. 195
Hester, M., see Oldham, R. K., et al. 242
Hewlett, J. S., see Mortimer, J., et al. 215
Hilgard, P., see Canetta, R., et al. 93
Hill, B. T., Whelan, R. D. H., Rupniak, H. T., Dennis, L. Y., Rosholt, M. A.: A Comparative Assessment of the in vitro Effects of Drugs on Cells by Means of Colony Assays or Flow Microfluorimetry 21
Holthuis, J. J. M., Sijstermans, A. W., Oort, W. J. van, Pinedo, H. M., McVie, G.: Sensitive High Performance Liquid Chromatographic Analysis of VM26, VP16-213, and Cis-Hydroxy Acid of VP16-213 Using UV and Electrochemical Detection 237
Hortobagyi, G. N., see Schell, F. C., et al. 223
Huang, C.-H., see Kalvin, D. M., et al. 41

Issell, B. F.: The Podophyllotoxin Derivatives VP16-213 and VM26 73
Issell, B. F., Rosenbaum, P. F., Dhafir, R. A.: Phase 3 Studies with Etoposide (VP16-213) in Lung Cancer Patients 239
Issell, B., see Schell, F. C., et al. 223
Issell, B., see Schell, F. C., et al. 244
Issell, B. F., Tihon, C., Curry, M. E.: Etoposide (VP16-213) and Teniposide (VM26) Comparative in vitro Activities in Human Tumors 113
Itri, L., see Chapman, R., et al. 205

Jardine, I., Strife, R. J.: Is the Lactone Moiety of VP16-213 Necessary for Activity? Synthesis and Activity of VP16-213 Cyclic Ether 235
Jardine, I., Strife, R. J., Colvin, M.: Analysis of VP16-213 and VM26 in Plasma by High Performance Liquid Chromatography with UV and or Fluorescence Detection 237
Jimenez, A., see Gracia, J. M. 199
Jonsson, K., see Eyben, F. E. von, et al. 195
Juarez Alonso, S., see González Larriba, J. L., et al. 240

Kalvin, D. M., Huang, C.-H., Lischwe, M. A., Peters, E. H., Prestayko, A. W., Crooke, S. T.: DNA Breakage Activity of the Methanol Extract of Auromomycin 41
Kashiwase, D., see Peters, J. H., et al. 65
Katin, M., see Swartz, M. R., et al. 238
Kelsen, D., see Chapman, R., et al. 205
Klastersky, J., see Nicaise, C. 240
Klastersky, J., see Nicaise, C. 242
Kohler, M., see Sikic, B. I., et al. 241
Krauss, S., see Oldham, R. K., et al. 242

Lanzos, E., see Cortés Funes, H., et al. 181
Lawrence, J. R., see Steele, W. H., et al. 61
Lawrie, S., Dodson, M., Arnold, A., Whitehouse, J. M. A.: Pharmacokinetics and Bioavailability of VP16-213 in Man 236
Lenaz, L., see Canetta, R., et al. 93
Lim, C. K., see Ayres, D. C. 99
Lindahl, S. Å., see Eyben, F. E. von, et al. 195
Lischwe, M. A., see Kalvin, D. M., et al. 41
Livingston, R. B., see Mortimer, J., et al. 215
Loike, J. D.: VP16-213 and Podophyllotoxin. A Study on the Relationship Between Chemical Structure and Biological Activity 103
Loo, T. L., see Stewart, D. J., et al. 31
Look, A. T., Dahl, G. V., Rivera, G., Mauer, A. M.: Clinical and Cell Kinetic Studies of the Effects of the Epipodophyllotoxin VP16-213 During Therapy of Refractory Acute Nonlymphocytic Leukemia 161
Look, A. T., see Evans, W. E., et al. 147
Luna, M., see Stewart, D. J., et al. 31

Maanen, J. M. S. van, Oort, W. J. van, Pinedo, H. M.: Studies on the Metabolism of VP16-213 in the Rat 236
Macbeth, F. R.: VM26: Phase I and II Studies 87
Mackay, I. R., see Goodyear, M. D. E., et al. 37
Madrigal Alonso, P. L., see Perez Manga, G., et al. 227
Madrigal Alonso, P., see Perez Manga, G., et al. 231

Madrigal, P. A., Manga, G. P., Palomero, I., Gomez, R. G.: VP16-213 Combined with Cis-Platinum (CDDP) in the Treatment of Small Cell Carcinoma of the Lung (SCLC) 203
Manga, G. P., see Madrigal, P. A., et al. 203
Mangioni, C., see D'Incalci, M., et al. 141
Mann, J., Piper, S. E.: A Novel and Facile Route to Podophyllotoxin 235
Marco, A. Di, Skovsgaard, T., Casazza, A. M., Pratesi, G., Nissen, N. I., Danø, K.: Cross Resistance and Cellular Uptake of 4'-O-Methyldoxorubicin in Experimental Tumors with Acquired Resistance to Doxorubicin 15
Mareel, M., Dragonetti, C., Cauwenberge, R. Van, Bruyne, G. De: Antiinvasive Effect of Podophyllotoxins in vitro 239
Marks, V., see Aherne, G. W. 117
Marsoni, S., see Morasca, L., et al. 209
Martinez, J., Escudero, C., Ramos, S. R., Panizo, A. G.: VP16-213 in the Therapy of Small Cell Lung Cancer (SCLC). Preliminary Results in Combination Chemotherapy 240
Masera, G., see D'Incalci, M., et al. 141
Mattsson, W., see Eyben, F. E. von, et al. 195
Mauer, A. M., see Look, A. T., et al. 161
Mavligit, G. M., see Patt, Y. Z., et al. 238
McElwain, T. J., see Barrett, A., et al. 243
McElwain, T. J., see Taylor, R. E., et al. 175
McElwain, T., see Williams, C. J., et al. 243
McNeill, C. A., see Steele, W. H., et al. 61
McVie, G., see Holthuis, J. J. M., et al. 237
Mendez, M., see Cortés Funes, H., et al. 181
Mendiola, C., see Cortés Funes, H., et al. 181
Montero Carcia, J. M., see González Larriba, J. L., et al. 240
Montie, J., see Mortimer, J., et al. 215
Moolenaar, A. J., Slooten, H. van, Seters, A. P. van, Smeenk, D.: Blood Levels of o,p'-DDD Following Administration in Various Vehicles After a Single Dose and During Long-term Treatment 51
Morasca, L., Marsoni, S., Pisoni, M. B., Piazza, E., Vago, G., Casali, W., Cogo, R., Bianchi, C., Scapaticci, R.: VP16-213 and Cyclophosphamide in non Oat Cell Bronchogenic Carcinoma 209
Mortimer, J., Bukowski, R. M., Montie, J., Hewlett, J. S., Livingston, R. B.: VP16-213, Cisplatinum, and Adriamycin Salvage Therapy of Refractory and/or Recurrent Nonseminomatous Germ Cell Neoplasms 215
Munzenrider, J. E., see Swartz, M. R., et al. 238
Murakami, M., see Yasue, M., et al. 5
Murphy, S. B., see Rivera, G., et al. 169

Nakazato, H., see Yasue, M., et al. 5
Newlands, E. S., Bagshawe, K. D.: The Role of VP16-213 (Etoposide; NSC-141540) in Gestational Choriocarcinoma 211
Newlands, E. S., see Begent, R. H. J., et al. 243
Nicaise, C., Klastersky, J.: Combination Chemotherapy with Cisplatin, Etoposide and Adriamycin in Small Cell Bronchogenic Carcinoma 240
Nicaise, C., Klastersky, J.: Chemotherapy with Etoposide and Cisplatin in non Small Cell Bronchogenic Carcinoma 242
Nissen, N. I., see Marco, A. Di, et al. 15
Nordqvist, S., see Allen, L. M., et al. 151

Okonmah, A. D., see Allen, L. M., et al. 151
Oldham, R. K., Greco, F. A., Einhorn, L., Perez, C., Birch, R., Hester, M., Krauss, S.: VP16-213 in Consolidation Therapy of Small Cell Lung Cancer 242
Oliver, R. T. D., see Williams, C. J., et al. 243
Oort, W. J. van, see Holthuis, J. J. M., et al. 237
Oort, W. J. van, see Maanen, J. M. S. van, et al. 236
Ordoñez Gallego, A., see González Larriba, J. L., et al. 240
Østerlind, K., see Pedersen, A. G., et al. 242
Ota, K., see Yasue, M., et al. 5

Palomero, I., see Madrigal, P. A., et al. 203
Panizo, A. G., see Martinez, J., et al. 240
Patt, Y. Z., Chuang, V. P., Mavligit, G. M.: Hepatic Arterial Infusion (HAI) of VP16-213 for the Treatment of Metastatic Disease Confined to the Liver 238
Peckham, M. J., see Barrett, A., et al. 243
Peckham, M. J., see Taylor, R. E., et al. 175
Peckham, M., see Williams, C. J., et al. 243
Pedersen, A. G., Østerlind, K., Dombernowsky, P.: A Phase II Study of VM26 in Previously Treated Patients with Small Cell Bronchogenic Carcinoma (SCC) 242
Peel, E. T., see Anderson, G. 239
Perez, C., see Oldham, R. K., et al. 242
Perez Manga, G., Madrigal Alonso, P. L., Alburquerque Carbuccia, H.: Mitomycin-C, VP16-213 Combination as Third Line Chemotherapy in Advanced Breast Cancer 227
Perez Manga, G., Madrigal Alonso, P. L., Alburquerque Cabuccia, H.: Adriamycin and VP16-213 Combination Treatment for Breast Cancer Previously Treated by the CMF Regimen 231
Peters, E. H., see Kalvin, D. M., et al. 41
Peters, J. H., Gordon, G. R., Kashiwase, D., Acton, E. M.: Tissue Distribution of Doxorubicin and Doxorubicinol in Rats Receiving Multiple Doses of Doxorubicin 65
Piazza, E., see D'Incalci, M., et al. 141
Piazza, E., see Morasca, L., et al. 209
Pinedo, H. M., see Holthuis, J. J. M., et al. 237
Pinedo, H. M., see Maanen, J. M. S. van, et al. 236
Piper, S. E., see Mann, J. 235
Pisoni, M. B., see D'Incalci, M., et al. 141
Pisoni, M. B., see Morasca, L., et al. 209
Pratesi, G., see Marco, A. Di, et al. 15
Prestayko, A. W., see Kalvin, D. M., et al. 41

Ramos, S. R., see Martinez, J., et al. 240
Rivera, G., Dahl, G. V., Murphy, S. B., Bowman, W. P., Aur, R. J., Avery, T. L., Simone, J. V.: VM26 Therapy in Children with Drug-refractory Lymphocytic Leukemia 169
Rivera, G., see Evans, W. E., et al. 147
Rivera, G., see Look, A. T., et al. 161
Rocchetti, M., see D'Incalci, M., et al. 141
Rosenbaum, P. F., see Issell, B. F., et al. 239

Rosenblum, M. G., see Stewart, D. J., et al 31
Rosenman, J., see Swartz, M. R., et al. 238
Rosholt, M. A., see Hill, B. T., et al. 21
Rubery, E. D.: Reversal of Recurrent Laryngeal Nerve Palsy Following VP16-213 Combination Therapy in a Patient with Metastatic Teratoma of the Testis 219
Rupniak, H. T., see Hill, B. T., et al. 21
Russel, I. S., see Goodyear, M. D. E., et al. 37
Rustin, G. J. S., see Begent, R. H. J., et al. 243

Sadée, W., see Au, J. L.-S. 55
Scapaticci, R., see Morasca, L., et al. 209
Schell, F. C., Yap, H. Y., Blumenschein, G. R., Esparza, L., Issell, B.: A Phase II Study of VP16-213 (Etoposide) in Refractory Metastatic Breast Carcinoma 244
Schell, F. C., Yap, H. Y., Hortobagyi, G. N., Issell, B., Esparza, L.: Phase II Study of VP16-213 (Etoposide) in Refractory Metastatic Breast Carcinoma 223
Sessa, C., see D'Incalci, M., et al. 141
Setchell, K. D. R.: Naturally Occurring Mammalian Lignans 235
Seters, A. P. van, see Moolenaar, A. J., et al. 51
Sijstermans, A. W., see Holthuis, J. J. M., et al. 237
Sikic, B. I., Daniels, J. R., Chak, L., Kohler, M., Carter, S. K.: VAM/POCC VS. POCC Chemotherapy of Small Cell Lung Carcinoma: Superiority of Early Alternation of Two Non-Cross-Resistant Combinations 241
Simone, J. V., see Rivera, G., et al. 169
Sinkule, J. A., see Evans, W. E., et al. 147
Skovsgaard, T., see Marco, A. Di, et al. 15
Slooten, H. van, see Moolenaar, A. J., et al. 51
Smeenk, D., see Moolenaar, A. J., et al. 51
Smyth, J. F., see Harper, P. G., et al. 179
Souhami, R. L., see Harper, P. G., et al. 179
Spiro, S. G., see Harper, P. G., et al. 179
Steele, W. H., Lawrence, J. R., Stuart, J. F. B., McNeill, C. A.: The Protein, Binding of Methotrexate in the Serum of Patients with Neoplastic Disease 61
Stewart, D. J., Rosenblum, M. G., Luna, M., Loo, T. L.: Disposition of Methylglyoxal bis(Guanylhydrazone) (MGBG, NSC-32946) in Man 31
Strife, R. J., see Jardine, I. 235
Strife, R. J., see Jardine, I., et al. 237
Stuart, J. F. B., see Steele, W. H., et al. 61
Suchi, T., see Yasue, M., et al. 5
Swartz, M. R., Rosenman, J., Gunderson, L. L., Katin, M., Munzenrider, J. E.: Podophyllin Increases Tumor Radioresponsiveness 238

Taylor, R. E., McElwain, T. J., Barrett, A., Peckham, M. J.: Etoposide as a Single Agent in Relapsed Advanced Lymphomas. A Phase II Study 175
Tejada, F., see Allen, L. M., et al. 151
Tennvall, L., see Eyben, F. E. von, et al. 195
Tihon, C., see Issell, B. F., et al. 113
Tirelli, U., Carbone, A., Franchin, G., Galligioni, E., Veronesi, A., Trovo, M. G., Volpe, R., Tumolo, S., Grigoletto, E.: VM26 in Malignant Hematological Diseases. A Phase II Study 173
Torrubia, A. P., see Cortés Funes, H., et al. 181
Torti, L., see Colombo, T., et al. 127
Trovo, M. G., see Tirelli, U., et al. 173
Tumolo, S., see Tirelli, U., et al. 173

Vago, G., see Morasca, L., et al. 209
Veronesi, A., see Tirelli, U., et al. 173
Volpe, R., see Tirelli, U., et al. 173

Wesley, M., see Aisner, J., et al. 187
Whelan, R. D. H., see Hill, B. T., et al. 21
Whitacre, M., see Aisner, J., et al. 157
Whitacre, M., see Aisner, J., et al. 241
Whitacre, M., see Aisner, J., et al. 187
Whitacre, M., see Echo, D. A. Van, et al. 237
Whitehouse, J. M. A., see Arnold, A. M. 123
Whitehouse, J. M. A., see Lawrie, S., et al. 236
Wiernik, P. H., see Aisner, J., et al. 157
Wiernik, P. H., see Aisner, J., et al. 187
Wiernik, P. H., see Aisner, J., et al. 241
Wiernik, P. H., see Echo, D. A. Van, et al. 237
Wilkinson, P., see Williams, C. J., et al. 243
Williams, C. J., Oliver, R. T. D., Wilkinson, P., McElwain, T., Peckham, M.: Phase I and II Studies of VP16-213 Plus Vinblastine, Bleomycin, and Cis Platinum in Advanced Testicular Teratoma 243

Yap, H. Y., see Schell, F. C., et al. 223
Yap, H. Y., see Schell, F. C., et al. 244
Yasue, M., Murakami, M., Nakazato, H., Suchi, T., Ota, K.: A Controlled Study of Maintenance Chemoimmunotherapy vs Immunotherapy Alone Immediately Following Palliative Gastrectomy and Induction Chemoimmunotherapy for Advanced Gastric Cancer. Tokai Cooperative Study Group for Adjuvant Chemoimmunotherapy of Stomach Cancer 5